Cocrystal pharma engages cro to conduct phase 2a human challenge influenza a clinical trial with novel, broad-spectrum antiviral candidate cc-42344

Bothell, wash., aug. 08, 2022 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”) announces it has engaged hvivo, a subsidiary of london-based open orphan plc (aim: orph), a rapidly growing specialist contract research organization (cro), to conduct a phase 2a clinical trial with the company's novel, broad-spectrum, orally administered antiviral candidate cc- 42344. this candidate represents a new class of investigational medicine designed to directly inhibit replication of the virus for the treatment of pandemic and seasonal influenza a.
COCP Ratings Summary
COCP Quant Ranking